Table 1.
Study characteristic | Number | % |
---|---|---|
Total studies registered in the USA | 54890 | 100 |
Sex of study subjects | ||
Females only | 5314 | 9.7 |
Males only | 2170 | 4.0 |
Both sexes combined | 47355 | 86.3 |
Not indicated | 51 | <0.1 |
Age of study subjects | ||
Adults (including seniors) | 42283 | 77.0 |
Children | 2952 | 5.4 |
Both adults and children | 9646 | 17.6 |
Not indicated | 9 | <0.1 |
Study phase | ||
Phase I | 8145 | 14.8 |
Phase II | 15911 | 29.0 |
Phase III | 8142 | 14.8 |
Phase IV | 4292 | 7.8 |
Phase not indicated | 18400 | 33.5 |
Source of funding | ||
Industry | 15903 | 29.0 |
Non-industry* | 32499 | 59.2 |
Blended (industry plus non-industry) | 6477 | 11.8 |
Source of funding not indicated | 11 | <0.1 |
1CTG began accepting trial registrations on 1 November 1999.
- 6480 trials for which NIH was the sole sponsor;
- 1227 trials sponsored by another US Federal agency;
- 10 166 trials with multiple non-industry sources of funding (including NIH); and
- 14 626 trials for which the funding source was listed as ‘other’ or was not listed.